סנדוגלובולין 1 גרם לתוך הוריד ישראל - עברית - Ministry of Health

סנדוגלובולין 1 גרם לתוך הוריד

mediline ltd. - immunoglobulin normal human 1 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

סנדוגלובולין 6 גרם לתוך הוריד ישראל - עברית - Ministry of Health

סנדוגלובולין 6 גרם לתוך הוריד

mediline ltd. - immunoglobulin normal human 6 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

סנדוגלובולין 3 גרם לתוך הוריד ישראל - עברית - Ministry of Health

סנדוגלובולין 3 גרם לתוך הוריד

mediline ltd. - immunoglobulin normal human 3 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

ווינרו ס.ד.ף. 5000 יחב"ל ישראל - עברית - Ministry of Health

ווינרו ס.ד.ף. 5000 יחב"ל

lapidot medical import and marketing ltd - anti-d immunoglobulins 5000 iu/vial - powder for solution for injection - anti-d (rh) immunoglobulin - prevention of the hemolytic disease of the newborn and treatment of immune thrombocytopenic purpura (itp).

מנסווקס ACWY מנה בודדת ישראל - עברית - Ministry of Health

מנסווקס acwy מנה בודדת

glaxo smith kline (israel) ltd - meningococcal vaccines group a 50 mcg/vial; meningococcal vaccines group c 50 mcg/vial - powder for solution for injection - meningococcus, tetravalent purified polysaccharides antigen - for active immunization of adults and children over two eyars against meningococcal meningitis caused by meningococci of serogroups a, c,w 135 and y meningococci.

אינפנריקס אי.פי.וי. איץ'.אי.בי ישראל - עברית - Ministry of Health

אינפנריקס אי.פי.וי. איץ'.אי.בי

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

פלודרה ישראל - עברית - Ministry of Health

פלודרה

sanofi - aventis israel ltd - fludarabine phosphate 50 mg/vial - powder for solution for inj/inf - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludara is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

סיטרבין להזרקה 1 גרם USP ישראל - עברית - Ministry of Health

סיטרבין להזרקה 1 גרם usp

genmedix - cytarabine 1 g/vial - powder for solution for injection - cytarabine - cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphcytic leukemia of adults and children. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia.

גמסיטאבין טבע ® 200 מ"ג/ויאל ישראל - עברית - Ministry of Health

גמסיטאבין טבע ® 200 מ"ג/ויאל

salomon,levin & elstein ltd - gemcitabine as hydrochloride 200 mg/vial - powder for solution for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

גמסיטאבין טבע ® 1000 מ"ג/ויאל ישראל - עברית - Ministry of Health

גמסיטאבין טבע ® 1000 מ"ג/ויאל

salomon,levin & elstein ltd - gemcitabine as hydrochloride 1000 mg/vial - powder for solution for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.